ESR1 and neoplasm: Many mechanisms have been proposed to account for endocrine resistance such as genetic (e.g., loss of ERα expression, mutation, expression of truncated ER isoforms), activation by peptide growth factors, and epigenetic (e.g., methylation, promoter inhibition) changes within the tumor that activate hormone-independent mitogenic pathways (4).